Artificial Intelligence (AI) is rapidly becoming embedded in FDA regulated business processes, from quality event management and change impact analysis to document review, complaint trending, and predictive insights. As adoption accelerates, life sciences organizations face a familiar but growing question: when does an AI model need to be validated, and what exactly does the FDA expect to see?
Recent draft of AI FDA Guidance provides a clear answer: AI risk is not about the algorithm, it is about the decision the AI supports and the context in which it is used. Validation is no longer a one-time technical exercise. It is about demonstrating that AI-enabled decisions are credible, controlled, and appropriate for their regulatory and quality impact.
FDA’s core principle: decision risk, not algorithm risk
FDA expects organizations to answer more fundamental questions:
- What decision is AI influencing?
- Where is the AI used within the business or quality process?
- How dependent is the outcome on the AI’s output?
- What is the impact if the AI is wrong?
When does an AI model require validation or formal assurance?
An AI model should be considered in scope for validation or formal assurance when its output influences:
- Patient safety
- Product quality
- Regulatory compliance
- Batch disposition or release decisions
Higher Burden: AI as a Sole Decision Maker
When an AI system is the sole determinant of a GxP relevant outcome, FDA expects a significantly higher level of assurance. In these scenarios, organizations must demonstrate that AI can be trusted without independent verification, a standard that is difficult to meet in most regulated environments.
Lower Burden: Advisory or Bounded AI
When AI is used in an advisory capacity within defined boundaries and paired with human review or independent controls, the regulatory burden is lower. However, lower burden does not mean no burden. Organizations must still show that the AI is fit for its intended use, risks are understood and mitigated, and accountability is clearly defined.
Practical opportunities for regulated organizations
Organizations adopting AI in regulated environments should prioritize:
- AI risk and gap assessments aligned to CSA principles
- Process-driven assurance strategies rather than document-heavy validation
- Strong data governance and security controls
- Integration assurance across connected systems
- Targeted, decisionfocused testing scenarios
These activities not only support compliance but also enable faster, safer AI adoption without over validating low risk use cases.
Key takeaways for executives
- FDA views AI risk as decision risk, not algorithm risk.
- Validation requirements depend on intended use, context, and impact.
- AI used as a sole decision maker carries significantly higher regulatory burden.
- Strong business processes and precise requirements are foundational.
- AI reduces manual effort but increases accountability and governance expectations.
Need help navigating a validation or assurance strategy for AI? Sikich can help.
This publication contains general information only and Sikich is not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or any other professional advice or services. This publication is not a substitute for such professional advice or services, nor should you use it as a basis for any decision, action or omission that may affect you or your business. Before making any decision, taking any action or omitting an action that may affect you or your business, you should consult a qualified professional advisor. In addition, this publication may contain certain content generated by an artificial intelligence (AI) language model. You acknowledge that Sikich shall not be responsible for any loss sustained by you or any person who relies on this publication.
